Platelets are crucial to the hemostatic response. Their role in coagulation is well documented and they have been considered for some time to promote resistance of thrombi to fibrinolysis. Platelets confer resistance to lysis by promoting clot retraction of the immediate fibrin network and through release of PAI-1 from their -granules. However, recent developments in the field now indicate that the role of platelets in fibrinolysis is much more diverse. Indeed, recent studies of different subpopulations of platelets that develop upon activation suggest that platelets can play varied roles in regulating hemostasis. Likewise the developments in our understanding of thrombus formation, architecture and changes in fibrin deposition and composition suggest that these different subpopulations of platelets may populate distinct areas within thrombi and potentially dictate the local hemostatic balance in these areas. This review will discuss the diverse roles of platelets in fibrinolysis and highlight the recent developments in the field and the contribution of both the intracellular pool of modulators as well as the membrane surface in regulating these processes.
INTRODUCTION
Platelets are at the nucleus of hemostasis, serving a multitude of functions to arrest bleeding and facilitate wound healing. Their vital role is evidenced by the fact that transfusion of platelets can dramatically restore hemostatic competency with higher platelet counts, correlating directly with an improvement in clinical bleeding. Interaction of platelets with the exposed components of the vessel wall post-injury generates the initial plug to limit blood loss. When platelets bind these matrix proteins they undergo rapid activation to release a host of clotting factors into the surrounding milieu. In addition, they change both the shape and composition of their membrane, allowing direct interaction with coagulation proteins. Platelets are a focal point for thrombin generation, interact directly with circulating fibrinogen facilitating generation of insoluble fibrin and act as an anchor for the growing scaffold of the clot. The crucial requirement of platelets for hemostasis is mirrored in the disease state of thrombosis where aberrant platelet function significantly augments thrombus formation with deleterious consequences. As a result, multiple antiplatelet agents are now used clinically to restrain the ability of platelets to participate in uncontrolled thrombus formation. 1 Interestingly, in addition to their fundamental role of platelets in clot formation, they contain a host of fibrinolytic factors that regulate fibrinolysis. Until recently that role has been presumed to be antifibrinolytic due to the high concentrations of fibrinolytic inhibitors, contained within platelets. [2] [3] [4] More recently additional profibrinolytic functions of platelets have been described which indicate that these unique anucleate cells may mediate fibrin dissolution as well as their established role in fibrin formation. 5, 6 This review will focus on the different means by which platelets can participate in the mechanisms that regulate fibrinolysis and recent work by our laboratory and others which suggest that platelets are central to regulation of both sides of the fibrinolytic process.
Crosstalk between fibrinolysis and clot retraction
The susceptibility of the fibrin network to lysis is dictated by its structure. 7 Platelets actively compress and reduce clot volume via a process termed retraction thereby consolidating the integrity of the hemostatic plug. 8 During clot retraction the fibrin network around the wound site is tightened via interactions with the integrin IIb3, previously termed platelet glycoprotein IIb/IIIa. Upon platelet activation, IIb3 undergoes a conformational change and binds extracellular fibrinogen 9 which initiates IIb3-mediated outside-in signalling. 10 IIb3 is connected to the intracellular actin cytoskeleton via talin 11 (Figure 1 ), allowing it to exert a contractile force on extracellular fibrin fibers. Platelet factor XIII-A (FXIII-A) modulates reorganization of the activated platelet cytoskeleton and IIbβ3 within sphingomyelin-rich lipid rafts, indicating that fibrin-IIbβ3-myosin act as an axis to support clot retraction. 12 Retracted clots are resistant to fibrinolytic degradation 13 and lyse more slowly than nonretracted clots 14 due to condensing of cross-linked alpha-2 antiplasmin (2AP) 15 and reduced binding of tissue plasminogen activator (tPA) to fibrin. 16 In platelet-rich clots the availability of plasminogen and plasminogen activators is reduced by clot retraction due to extrusion of these proteins. These studies indicate the integral role of platelets in clot retraction and how this impacts progression of fibrinolysis.
 -GRANULE PROTEINS
There are three types of secretory granules, namely the -granules, dense granules and lysosomes ( Figure 1 ). -granules are the most abundant with around 50-80 per cell accounting for 10% of the platelet volume, in contrast dense granules comprise only 1%. 17 Upon activation platelets release more than 300 proteins the majority of these arising from -granules. -granule content is derived by several mechanisms including biosynthesis within their precursor cells megakaryocytes [18] [19] [20] , endocytosis 21, 22 , and pinocytosis, 23 at both the megakaryocyte and platelet level.
Differential packaging of -granule proteins including von Willebrand factor (VWF), fibrinogen, vascular endothelial growth factor, endostatin, thrombospondin-1, and basic fibroblast growth factor from specific -granule subpopulations has been reported. 24, 25 More intriguingly pro-and anti-angiogenic proteins were observed in distinct -granule populations and were differentially released. 25 Indeed, a similar mechanism for storage and release of pro-and anti-fibrinolytic proteins may potentially exist and warrants further investigation. In the remainder of this section we describe fibrinolytic proteins that are both endocytosed and biosynthesized within platelets and their contribution to fibrinolysis (Table   1) .
Fibrinogen
Platelets have a pool of fibrinogen which is endocytosed from plasma into platelets and megakaryocytes 26 and stored within -granules and the cytoplasm. Platelet fibrinogen accounts for 3-10% 27,28 of total platelet protein (5-25 mg/10 11 platelets) with approximately 25% 27 being found in -granules 29, 30 . The integrin IIb3 is involved in endocytosis of fibrinogen, as patients with Type 1 Glanzmann thrombasthenia (who exhibit defective copy numbers of IIb3) have significantly reduced levels of fibrinogen within their platelets. [31] [32] [33] In megakaryocytes, fibrinogen is endocytosed and trafficked to multivesicular bodies, which are precursors to mature -granules. 34 There are potentially other receptors involved in the endocytosis of fibrinogen, such as the integrin Vβ3, which may facilitate binding of soluble fibrinogen to the inactive conformation of IIb3, thereby enhancing uptake of fibrinogen. 35 Consistent with this hypothesis, deficiency of both Vβ3 and IIb3 further attenuates fibrinogen accumulation in platelets. 36 Further work is required to define the receptors involved in the uptake of fibrinogen and its relative distribution within quiescent platelets.
Both the cytosolic and -granule pools of fibrinogen are released in response to platelet stimulation 29, 30 and is partially retained on the activated membrane due to its interaction with IIb3.
Plasminogen
Plasminogen has been identified in -granules by proteomic approaches 37,38 but the relative amounts have not been defined, although it is reportedly released after stimulation 39 .
Plasminogen is not detected in megakaryocytes, unless cultured in plasma containing plasminogen, indicating that it is endocytosed by the cells. 38 There are two forms of plasminogen, the native predominant form Glu-plasminogen and the intermediate form Lysplasminogen, which is formed by cleavage of the activation peptide from Gluplasminogen. 40 Glu-plasminogen is cleaved at Arg561-Val562 to form two chain Glu-plasmin followed by a further cleavage at the N-terminus to form fully active lys-plasmin. 40, 41 Lysplasminogen has a more open conformation which is more readily activated by plasminogen activators. It is presently unknown whether the -granular pool is Glu-or Lys-plasminogen or if it differs from the plasma forms.
Inhibitors of fibrinolysis
A number of fibrinolytic inhibitors exist within platelets and as a result of this platelet-rich thrombi are reportedly more resistant to tPA-mediated lysis than erythrocyte-rich thrombi. 42 The platelet content of thrombi and their resistance to lysis may help to explain why recanalization in some stroke patients fails. 43 
Plasminogen activator inhibitor-1 (PAI-1)
The serine protease inhibitor, PAI-1, is the principal inhibitor of tPA and urokinase plasminogen activator (uPA). PAI-1 is abundant in -granules (0.67 ng/10 6 platelets) and is released upon platelet activation, accounting for the majority of circulating PAI-1. 2 Platelets contain PAI-1 mRNA and are capable of de novo synthesis of functionally active PAI in vitro which largely remains in an active conformation. 44, 45 Platelet PAI-1 is functionally less active than the plasma PAI-1, 2,46 but accounts for approximately 50 % of total PAI-1 activity due to its sheer abundance. 2 Arterial thrombi which contain platelet dense regions 47 found to contain 2-3-fold more PAI-1 than venous thrombi. 48, 49 
Alpha 2 antiplasmin (2AP)
2AP is the principal inhibitor of plasmin and can be found within -granules. 50, 51 On average there is 62 ng 2AP/ 10 9 platelets which accounts for 0.05 % of the plasma level on a volume basis. 50 Platelet 2AP is released upon activation 50 and stabilizes platelet-rich clots against fibrinolysis. 52, 53 The contribution of the platelet pool of 2AP to thrombus stability may be limited, as addition of normal circulating platelet concentrations to 2AP-depleted plasma does not stabilize thrombi against lysis. 54 Platelet 2AP may potentially play a role in maintaining the structural integrity of the platelet plug by down-regulating lysis during the initial stages of thrombus formation, rather than protecting the established thrombus against premature lysis.
Thrombin activatable fibrinolytic inhibitor (TAFI)
TAFI is a pro-carboxypepetidase that can be activated by thrombin, a reaction that is accelerated in excess of 1000-fold by thrombomodulin 55 or alternatively by plasmin. 56 The activated carboxypepetidase, TAFIa, removes C-terminal lysine residues from fibrin that has been partially degraded reducing the availability of binding sites for tPA and plasminogen. 57 TAFI is present in platelets at approximately 50 ng/ 10 9 platelets and is released from -granules upon activation 4 in concentrations sufficient to down-regulate fibrinolysis of platelet-rich thrombi. 58 Megakaryocytes contain TAFI mRNA and biosynthesis of this protein is thought to account for the pool of TAFI residing in granules. 4, 58 
Histidine rich glycoprotein (HRG)
The plasma glycoprotein HRG plays a role in multiple physiological processes including coagulation and fibrinolysis. HRG is endocytosed by platelets and megakaryocytes 59 , with this pool accounting for 0.14% of the plasma level. 60 HRG is released upon platelet activation 59, 60 and directly associates with the membrane of activated platelets. 61 Interestingly, HRG -/-mice exhibit longer tail bleed times, indicative of defective platelet activation, increased antithrombin activity, shorter prothrombin times and enhanced spontaneous fibrinolysis. 62 As HRG is known to bind to fibrinogen 63 and is retained on the fibrin surface after clot formation 64 , co-localization with fibrinogen in -granules mean they could potentially be released as a complex following stimulation. HRG also acts as an competitive inhibitor of plasminogen by binding to lysine binding site 1, potentially downregulating association of plasminogen and fibrin. 65 Conversely, it is reported to tether plasminogen to the cell-surface, thereby enhancing the migratory potential of cells. 66 Further work is required the significance of this protein in regulating fibrinolysis.
Platelet C1-inhibitor
C1-inhibitor is a serpin which inhibits serine proteases of the complement, contact, and fibrinolytic systems. C1-inhibitor is contained in -granules 67 and is secreted upon activation with a portion (23%) retained on the membrane. 3 The platelet pool of C1-inhibitor is derived from megakarocyte biosynthesis with platelets containing 62 ng/ 10 8 platelets compared to the relatively high plasma concentration of 290 g/ml. 3 C1-inhibitor forms a complex with tPA in situations when it is in excess over PAI-1. [68] [69] [70] A recent report suggests that C1-inhibitor is the principal inhibitor of a single-site, Lys300 -> His mutant (M5) form of scuPA, which is less vulnerable to non-specific activation to uPA. 71 Infusion of C1-inhibitor prior to administration of the mutant form of scuPA prevented non-specific activation of plasminogen and fibrinogenolysis whilst permitting lysis of partially-degraded fibrin. 72 
Protease nexin-1 (PN-1)
Protease nexin-1 (PN-1), also called serpinE2, is a serpin inhibitor with a broad spectrum of substrates including thrombin, factor Xa, factor XIa and activated protein C, as well as the fibrinolytic proteins plasmin, tPA and uPA (reviewed by 73 ). Interestingly, PN-1 is the closest homologue of PAI-1 73 eluding to a function in regulation of fibrinolysis. It is expressed by most blood cells including platelets 74, 75 where the majority is contained within -granules, but a small amount exists on the quiescent platelet membrane. 76 The concentrations of PN-1 released in the secretome are relatively high (20 nmol/L per 3 x 10 8 platelets) 73 but a pool is retained on the activated membrane surface. 74 Platelet PN-1 has the capacity to inhibit both tPA-mediated fibrinolysis and directly down-regulates plasmin generation and activity on fibrin. 77 A blocking antibody to PN-1 enhances lysis of platelet-rich clots and PN-1 -/-mice exhibit accelerated lysis compared to wild-type. 77 Indeed, a deficiency in PN-1 significantly augments t-PA mediated thrombolysis 77 emphasizing its clear inhibitory role in fibrinolysis.
DENSE GRANULES
Dense granules (or dense bodies) are less abundant than -granules, with only around [6] [7] [8] per platelet, at around 250 nm in size, and are identified in electron micrographs by virtue of their electron dense cores. Dense granules are comprised of cations (Ca 2+ , Mg 2+ K + ), phosphates (polyphosphate (polyP) and pyrophosphate), bioactive amines (serotonin and histamine) and nucleotides (ATP, ADP, UTP, GTP). High concentrations of these constituents are achieved by active transport mechanisms which also maintains the granule lumen at a pH of around 5.4. The components of dense granules ,in particular serotonin, ADP, Ca 2+ and polyP regulate hemostasis, which will be described in more detail below.
Polyphosphate (polyP)
PolyP is an inorganic phosphate molecule comprising of a repeating units of phosphate monomers joined by phosphoanhydride bonds. 78 79 79,80 PolyP elicits numerous effects on coagulation and fibrinolysis inducing significant augmentation of the clotting process by enhancing factor XII (FXII) activation, preventing inhibition of factor Xa (FXa) by tissue factor pathway inhibitor (TFPI), and acting as a cofactor for thrombin-mediated activation of factor XI (FXI). 81 These procoagulant effects have a downstream impact on fibrinolysis by enhancing TAFIa activation due an acceleration of thrombin generation. 81 Polymer length is an critical determinant of polyP function; longer polymers are significantly more effective in activation of FXII. 82 PolyP binds to fibrinogen 83 and alters the structure of the fibrin network, in doing so it attenuates binding of tPA and plasminogen to fibrin, thereby delaying tPAmediated fibrinolysis. 83 PolyP binds to FXII, 80, 84 facilitates its autoactivation 84 and has been shown to augment FXII-driven coagulation. 81, 85 Despite being classified as a coagulation factor, activated FXII (FXIIa) demonstrates weak plasminogen activator activity. 86, 87 Recently, it has been shown that FXIIa can augment tPA-mediated fibrinolysis by generating additional plasmin. 88 Our recent work has shown that polyP can activate FXII 84 and subsequently acts as a cofactor in enhancing its plasminogen activator activity which is the first profibrinolytic function of polyP to be documented.
CYTOPLASMIC PROTEINS Factor XIII (FXIII)
Activated FXIII (FXIIIa) increases the mechanical stability of clots by forming -(-glutamyl) lysyl bonds in fibrin 89 through cross-linking the lysine -amino group of one fibrin strand to the glutamine -carboxymide group of another. 90 FXIII is present in platelets [91] [92] [93] at high concentrations (around 60 fg per platelet) 94 and is largely contained within the cytoplasm. 29, 95 Unlike the heterodimer A2B2 form that circulates in plasma, the cellular form exists as a homodimer of FXIII-A. 29, 95 A small pool of the A2B2 form is reported to be contained in -granules 29,96 which is presumed to be taken up from plasma in association with fibrinogen. 96 Early studies indicated that FXIII-A is retained in the platelet cytoplasm following activation and is not detectable in the secretome. 97 FXIII-A does not contain an identifiable endoplasmic reticulum (ER) signaling sequence and is excluded from the ER-Golgi pathway in nucleated cells. 98 However, it has been found to be directed toward the plasma membrane in association with Golgi vesicles in monocyte-macrophages. 99 Due to the lack of ER-leader sequence FXIII-A cannot be targeted to -granules in nascent platelets during de novo synthesis in megakaryocytes. This evidence has led to the assumption that release of FXIII-A from platelets was improbable and its functions were likely to be intracellular and distinct from the role of the plasma FXIII in hemostasis. Plasma FXIII plays an essential role in the regulation of fibrinolysis where it cross-links inhibitors of fibrinolysis to fibrin, including 2AP 100 , TAFI 101 , and PAI-2. 102 We have shown that the antifibrinolytic function of plasma FXIIIa is mediated by cross-linking 2AP to fibrin 103 and in its absence thrombi lyse rapidly. 104 Platelet FXIII-A was shown to induce high molecular weight -dimer, -polymers and 2AP-fibrin cross-links. 52, 53, [105] [106] [107] Our work has now shown that platelet FXIII-A is externalized on the activated platelet membrane and mediates extracellular fibrin cross-linking reactions stabilizing thrombi against fibrinolysis in an 2AP-dependent manner. 54 
Tissue factor pathway inhibitor (TFPI)
Two alternatively spliced isoforms of TFPI exist in blood: TFPI and TFPIβ. 108, 109 Platelets exclusively express the TFPI isoform which is derived from megakaryocytes and accounts for approximately 7-10 % of the total pool of TFPI in whole blood. 110, 111 At this time, it is unknown where TFPI is located within quiescent platelets but evidence suggests it is not found in -granules or lysozymes, as it does not co-localize with VWF, fibrinogen, or lysosomal-associated membrane protein-1 (LAMP-1). 110 TFPI is exposed on the surface of platelets following strong stimulation with thrombin or dual agonists via an unknown mechanism. 110 In addition to platelet surface expression, a soluble form of TFPI is released in response to strong agonist stimulation, allowing accumulation of the inhibitor at sites of vascular injury to act directly on tissue factor/factor VIIa complex and attenuate thrombus propagation. TFPI-2, a homologue of TFPI-1, has recently been identified within platelets and is of megakaryocytic origin. 112 TFPI-2 is released from platelets in response to TRAP-6 stimulation and strongly attenuates tPA-mediated plasma clot lysis by directly inhibiting plasmin. The levels of TFPI-2 rise steadily during pregnancy potentially indicating an antifibrinolytic role for this kunitz inhibitor in control of bleeding during labour. 112 
FIBRINOLYTIC PROTEINS ON THE MEMBRANE SURFACE
The activated membrane surface of platelets is well documented in terms of its binding of coagulation factors, via Gla-domains and integrin binding to fibrinogen, VWF, and collagen.
Perhaps less well explored is the ability of the platelet membrane to serve as a binding site for fibrinolytic proteins.
Urokinase plasminogen activator (uPA)
The plasminogen activator uPA is a 54 kDa serine protease found in urine and synthesized by fibroblast-like cells, monocytes, macrophages 113, 114 , and epithelial cells. 115 The single chain form of uPA, scuPA, is activated to two chain uPA by cleavage at Lys158-Ile159. 116 Normal platelets contain a small amount (1.3 ng uPA/10 9 platelets) of uPA 117 but negligible levels are found in megakaryocytes. Quebec platelet disorder is associated with enhanced expression and storage of uPA and manifests as delayed onset of bleeding after injury.
Increased expression of uPA, develops during differentiation of megakaryocytes from hematopoietic progenitors and is linked to a tandem duplication in the PLAU gene. 38 The limited plasminogen activator concentration in normal platelets may serve a protective function, as Quebec platelet disorder results in intracellular generation of plasmin which is associated with degradation of -granule proteins. 118 In sharp contrast to the inhibitory effect of platelets on t-PA-and uPA-mediated fibrinolysis we and others have shown that scuPA-mediated lysis is dramatically enhanced by platelets. 5, 119 This seems counterintuitive considering the high concentrations of fibrinolytic inhibitors in platelets, but is explained by surface-mediated reciprocal activation of plasminogen and scuPA on the membrane surface. 5 scuPA is present on the membrane of unstimulated platelets 120 , however binding is not accounted for by the known cellular receptor uPAR 121 , as uPAR is not expressed on platelets. Exogenous scuPA is endocytosed by platelets, by an underdetermined mechanism, which may prolong its activity. 122 Once formed, cell-bound plasmin is protected from inhibition by 2AP, although (sc)uPA is susceptible to inhibition by PAI-1 and PAI-2. An additional mechanism of activation of thrombin-cleaved scuPA by platelet cathepsin C has also been described on the surface of thrombin-stimulated platelets. 123 Despite these lines of evidence locating (sc)uPA on the membrane of quiescent and activated platelets, the receptors responsible are still unknown.
Tissue-type plasminogen activator (tPA)
tPA, a 68 kDa serine protease, is largely produced and secreted by endothelial cells 124 however, small amounts of active tPA have been detected in megakaryocytes. 125 tPA is secreted as a single-chain form (sctPA) that is cleaved at Arg275-Ile276 to a two-chain form (tctPA). When associated with fibrin, both forms exhibit comparable activity, 126 as binding of sctPA to fibrin decreases the Km of activation, enhancing plasmin generation and downstream fibrinoysis. 127 tPA binds to the surface of quiescent platelets potentiating plasminogen activation approximately 8-fold. 128, 129 Reversible binding of tPA to the membrane appears to be by a single-class of saturable, low affinity binding sites that are amplified upon thrombin stimulation and partially displaced by plasminogen. 129, 130 Receptors for tPA on platelets have not been definitively identified, but annexin II has been described as a plasminogen-tPA co-receptor on endothelial cells. 131 Platelet-rich regions within clots are associated with densely packed retracted fibrin fibers which attenuate tPA binding and decrease lysis front velocity. 16, 132 Interestingly, a second late phase acceleration of fibrinolysis is observed which is attributed to clustering of lysing fibers which augments the local concentration of fibrin-bound tPA. 132 The relative contribution of fibrin versus the cell surface in accelerating local fibrinolysis is an intriguing question but one that is difficult to tackle experimentally.
PLATELET SUBPOPULATIONS
Upon activation of platelets, a number of phenotypically different subpopulations arise [133] [134] [135] [136] which have different functions within the microenvironment of the thrombus.
Procoagulant platelets express phosphatidlyserine (PS) 137 , readily binding coagulation factors, thereby enhancing thrombin generation and downstream fibrin formation.
Adherent platelets expose activated IIbβ3, bind fibrin and other platelets thereby consolidating the thrombus and protecting against premature degradation. 138
Aggregating platelets
Aggregating platelets are PS-negative with a characteristic spread morphology (Figure 2A ).
They bind fibrinogen via activated IIbβ3 and generate fibrin on their surface. 138 Aggregating platelets expose FXIII-A in a diffuse pattern over their surface 54 , whilst plasminogen and PAI-1 localize centrally over the granulomere (Figure 3 ). 6 Binding of plasminogen is attenuated by blocking IIbβ3 with tirofiban, however it is not dependent on the active conformation of the integrin. This is evidenced by the fact that plasminogen accumulates on the surface of aggregating platelets prior to PAC-1 antibody which binds only the active integrin. 6 The functional significance of these fibrinolytic proteins in aggregating platelets requires further clarification. However, their importance in thrombus architecture and stability is exemplified by addition of abciximab, a IIbβ3 receptor antagonist, which significantly accelerates lysis by prohibiting the interaction between fibrin(ogen) and platelets. 139 
PS-exposing platelets
Upon exposure to a collagen surface or glycoprotein VI ligands, platelets initially form pseudopods and lamellipodia before morphing to a characteristic 'balloon' shape and flipping PS to the activated membrane ( Figure 2B ). 140 PS-exposing platelets, or procoagulant platelets, exhibit prolonged increases in cytosolic Ca 2+ and support binding of the prothrombinase complex. 136, 138, 141 After the appearance of aggregating platelets, which incorporate fibrinogen, further platelets are recruited that subsequently become PSpositive. 138 These platelets allow formation of 'star-like' fibrin network which emanates from the platelet surface under low shear. This process is dependent on both FXIIIaand IIbβ3 142 , as in their absence fibrin fibers orientate in the direction of flow. 143 These observations indicate that PS-exposing platelets contribute to the dynamic structure of the fibrin network by guiding multi-directional fibrin polymerization and may have downstream consequences in terms of modulating fibrinolysis. Platelet FXIII-A and calpain have a role in limiting excessive accumulation of platelets by decreasing adhesion via IIbβ3. 134 Interfering with PS exposure on platelets impairs FXa and thrombin generation thereby downregulating thrombus formation in murine models of thrombosis. 144, 145 These thrombi are prone to embolization, exhibit reduced stability and increased susceptibility to lysis
Coated platelets
'Coated platelets' are procoagulant platelets produced by strong dual agonist stimulation. 133, 146, 147 Coated platelets retain a 'coat' of cross-linked -granule proteins on their surface 143, 146, 148 which is reported to develop secondary to PS exposure. 149 The protein coat consist of procoagulant proteins such as factor V, VWF, and fibrinogen which are reportedly cross-linked to the surface in a FXIIIa-dependent manner. The presence of fibrinolytic proteins such as PAI-1, HRG, and plasminogen on coated platelets is less well described, but they too could be present within the 'coat'. The percentage of coated platelet potential in individuals ranges from 15 -53%.l. 147 The full physiological role and capacity of coated platelets is not fully understood, however, they are thought to be prothrombotic in nature. 150 -151 Therefore, the ability to target and enhance the profibrinolytic potential of this subpopulation may have therapeutic value.
Protruding 'cap' on procoagulant platelets
Procoagulant PS-exposing platelets have been found to possess a protruding 'cap' which is rich in fibrinogen and thrombospondin. 152 We have recently confirmed the presence of fibrinogen and demonstrated the localization of FXIII-A 54 , plasminogen, and PAI-1 6 in these protruding caps (Figure 3) . These 'caps' have since been demonstrated to contain numerous coagulation factors IXa, Xa/X, Va and VIII. 153 Fibrin may act as an anchor for these proteins within the platelet 'cap' and could potentially facilitate the transfer of plateletderived proteins into the adjoining fibrin network. Indeed activation of platelets with TRAP-6 rather than thrombin or inhibition of fibrin polymerization with Gly-Pro-Arg-Pro reduced exposure of platelet FXIII-A 54 and attenuated plasminogen binding within the 'cap'. 6 However, despite the presence of fibrin(ogen), IIbβ3 appears to be in an inactive conformation. Platelets stimulated with strong dual agonists display secondary inactivation of the integrin after occupation with a ligand such as fibrinogen. 134, 146, 154, 155 Blocking IIbβ3 or fibrin polymerization reduces plasminogen binding to PS-exposing platelets 6 and consistent with this Glanzmann thrombasthenia patients who lack IIbβ3 display reduced plasminogen binding. 156 These protein rich 'caps' on the surface of PS-exposing platelets are not fully understood but their collection of fibrinolytic mediators implies a functional role in fibrinolysis. Within a developing thrombus, the PS-exposing platelets are visualized as distinct non-aggregating platelets that localize in strings at the edges of clots 138 and may limit excessive clot expansion by curbing association of additional platelets while permitting further generation of fibrin. The collection of proteins in these protruding 'caps' suggest they may act as a delivery service for fibrinolytic proteins into the heart of the thrombus.
THROMBUS ARCHITECTURE, LOCALIZATION OF PLATELETS AND FIBRINOLYTIC PROTEINS
During thrombus formation a core of densely packed, highly activated platelets forms which is enveloped by a shell of loosely packed less activated platelets. 157 The rate of solute transport within the core of the thrombus is low 158 indicating that proteins associated with the platelet membrane or within the gap junctions of these tightly packed aggregates will be retained. These platelets experience strong agonist stimulation evoking prolonged intracellular calcium spikes, shape change and rapid degranulation. 159 In the shell of the thrombus, platelets are less intensely stimulated, displaying only transient increases in intracellular calcium with little or no degranulation. 159 This is an important concept, as it indicates that platelets do not release their intracellular contents into flowing blood, but rather into the body of the thrombus where local concentrations of platelet-derived proteins are likely to define the hemostatic balance.
Upon thrombin stimulation the copy number of IIb3 on the membrane increases 2-3-fold, presumably drawing from the pool within -granules. 160 The concurrent sharp rise in intracellular Ca 2+ induces the active conformation of IIbβ3 161 and interaction with fibrinogen. 9 Thrombin concentrations are elevated within the core of the thrombus facilitating further fibrin formation and platelet activation thereby dictating the overall structure and its resistance to fibrinolysis.
Plasminogen associates with unstimulated platelets, but following thrombin stimulation binding is significantly augmented in a fibrin and IIb3-dependent manner. 6, 162, 163 An array of plasminogen receptors have been identified on different cell types and generally involve an interaction of plasminogen with C-terminal lysine residues of membrane-bound proteins. 164 The plasminogen content of a thrombus dictates its susceptibility to lysis 165 and is likely related to its ability to be retained on the surface of fibrin and cells. Our laboratory studied the localization of plasminogen in a physiological flow model of thrombus formation and lysis. 6 Plasminogen accumulated on platelet-associated fibrin, with a smaller pool found in direct association with the platelet surface (Figure 4) . 6 Plasminogen was initially visualized in the 'core' of the thrombus in direct association with platelets, but as time progressed it was evident at areas distal to the core localizing with fibrin; both fibrin and plasminogen accumulation in these areas was blocked by inclusion of hirudin during thrombus formation. 6 Using this flow model we have shown that both fibrin and cellular surfaces are important for retention of plasminogen within thrombi and that its local concentration governs the rate of fibrin degradation.
Stimulation of platelets with strong dual agonists, thrombin and convulxin, generates measurable quantities of plasmin which is significantly augmented by addition of plasminogen activators. 6 We have previously shown a relationship between plateletassociated plasminogen and scuPA 5 , as described earlier in this review. Cell-bound uPA recognizes and activates both lys-plasminogen and ACA-liganded plasminogen, which has an open conformation similar to lys-plasminogen. 166 Association of plasminogen with the platelet surface induces an open conformation which is more readily cleaved to plasmin. 5, 162, [166] [167] [168] [169] Platelet-bound plasminogen can also be activated by crosstalk with uPA bound to monocytes or endothelial microparticles. 166 tPA-mediated plasminogen activation is also enhanced by platelets and is thought to arise from an autocatalytic mechanism. 168 In addition to the surface enhancement of plasminogen activation, the platelet surface acts as a reservoir of plasmin that is protected from inhibition by 2AP thereby promoting fibrinolysis. 170, 171 PAI-1 accumulates to high concentrations in platelet-rich thrombi 49, 165 and its concentration directly correlates with their lysability. 165, 172 PAI-1 is not cross-linked to fibrin like 2AP, but associates indirectly via its cofactor, vitronectin 173 , which also preserves the activity of this labile serpin inhibitor. 174, 175 Upon release from -granules PAI-1 localizes on platelet-bound fibrin thereby increasing the local resistance of this network to fibrinolytic degradation. 176 TAFI is also released from -granules in response to stimulation 4, 6 and exerts an additional antifibrinolytic function to that of the plasma pool. 58 Thrombin generation on the platelet membrane and concomitant release of TAFI with platelet-derived TM 177 , may accelerate generation of TAFIa in platelet-rich areas. Plasmin activity generated on the surface of activated platelets 6 may also function in local TAFI activation and indeed our laboratory has previously shown that both thrombin/TM and plasmin-mediated TAFI activation regulate thrombus lysis. 178 TAFIa has also been found to play a significant role in resistance of platelet-rich clots to lysis. 179 Indeed, dual targeting of PAI-1 and TAFIa using antibody approaches has shown to be beneficial and is currently under investigation as novel thrombolytic agent for the prevention of ischaemic stroke. 180, 181 Platelet FXIII-A stabilizes thrombi against fibrinolysis by cross-linking 2AP to fibrin of plasma and platelet origin. 52, 53, 105 . These extracellular cross-linking reactions are achieved by translocation of FXIII-A from the cytoplasm to the outer-leaflet of the stimulated platelet membrane. FXIII-A is not detected in the secretome indicating that externalization to the membrane is sufficient for the transglutaminase to mediate extracellular cross-linking reactions. 54 The distribution of FXIII-A on the surface of platelets differed in relation to the subpopulation and further work is necessary to determine which of these is important for mediating the antifibrinolytic function of FXIII-A. 54 Understanding the function of platelet subpopulations could allow for thrombolytic therapies to be tailored to target populations. A recent report showed that thrombolysis with scuPA fused to single chain antibody fragments (scFv), which target activated αIIbβ3, was dependent on platelet-bound plasminogen. 182 The possibility that platelets could serve in the rapid delivery of specific pro-or anti-fibrinolytic protein packages provides an exciting opportunity to harness their potential therapeutic value. 
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